Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults Journal Article
| Authors: | Kolb, E. A.; Kushner, B. H.; Gorlick, R.; Laverdiere, C.; Healey, J. H.; LaQuaglia, M. P.; Huvos, A. G.; Qin, J.; Vu, H.; Wexler, L.; Wolden, S.; Meyers, P. A. |
| Article Title: | Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults |
| Abstract: | Purpose: To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d. Results: Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82%; overall survival (OS) is 89%. The 4-year EFS rate for patients with distant metastases is 12%; the OS rate is 17.8%. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy. Conclusion: Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs. © 2003 by American Society of Clinical Oncology. |
| Keywords: | adolescent; adult; cancer chemotherapy; cancer survival; child; controlled study; preschool child; bone neoplasms; child, preschool; disease-free survival; bone tumor; survival rate; major clinical study; clinical trial; disease course; mortality; doxorubicin; disease free survival; antineoplastic agent; prospective study; prospective studies; metastasis; controlled clinical trial; multiple cycle treatment; phase 2 clinical trial; etoposide; antineoplastic combined chemotherapy protocols; recurrence; combination chemotherapy; cyclophosphamide; vincristine; continuous infusion; pathology; ifosfamide; ewing sarcoma; intensive care; disease progression; remission; remission induction; recurrent disease; sarcoma, ewing's; humans; human; male; female; priority journal; article; ivad protocol |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 21 |
| Issue: | 18 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2003-09-15 |
| Start Page: | 3423 |
| End Page: | 3430 |
| Language: | English |
| DOI: | 10.1200/jco.2003.10.033 |
| PUBMED: | 12972518 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 12 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work